The Respiratory & Allergy Division focuses on the development, manufacturing, and distribution of high-quality pharmaceutical products for the prevention and treatment of respiratory and allergic diseases. Operating through GMP-certified manufacturing facilities and in compliance with DRAP regulations and the Drug Licensing Management (DML) Rules 2019, the division is committed to delivering safe, effective, and reliable healthcare solutions.
The division addresses a wide range of respiratory and allergic conditions, including asthma, allergic rhinitis, seasonal allergies, chronic respiratory inflammation, and airway hypersensitivity disorders. Through innovation, stringent quality standards, and patient-centered care, the division supports healthcare professionals in providing optimal respiratory management and long-term disease control.
Main Products
Featured Product – Montelukast
Montelukast is a leukotriene receptor antagonist indicated for the prevention and long-term management of asthma and allergic rhinitis. It helps reduce airway inflammation, relieve allergy symptoms, improve breathing, and support better control of respiratory conditions.